Profund Advisors LLC Increases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Profund Advisors LLC raised its holdings in Kenvue Inc. (NYSE:KVUE) by 9.9% in the second quarter, HoldingsChannel reports. The institutional investor owned 22,073 shares of the company’s stock after acquiring an additional 1,987 shares during the quarter. Profund Advisors LLC’s holdings in Kenvue were worth $401,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in KVUE. Manchester Capital Management LLC lifted its stake in shares of Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the period. Mather Group LLC. purchased a new position in Kenvue in the 1st quarter worth $28,000. Riverview Trust Co acquired a new stake in Kenvue during the 1st quarter worth about $33,000. MV Capital Management Inc. grew its stake in Kenvue by 71.2% during the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after purchasing an additional 642 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the first quarter valued at about $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE KVUE opened at $23.12 on Friday. The stock has a market capitalization of $44.27 billion, a price-to-earnings ratio of 29.64, a PEG ratio of 2.92 and a beta of 1.40. The stock has a 50-day moving average of $21.21 and a 200 day moving average of $20.03. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $23.55.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the prior year, the company posted $0.32 EPS. The business’s quarterly revenue was down .3% on a year-over-year basis. Sell-side analysts anticipate that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were given a $0.205 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.55%. Kenvue’s dividend payout ratio (DPR) is 105.13%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on KVUE shares. Deutsche Bank Aktiengesellschaft lifted their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. UBS Group upped their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group started coverage on shares of Kenvue in a report on Tuesday. They set a “buy” rating and a $27.00 target price for the company. Citigroup lowered their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. lifted their price objective on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $22.10.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.